share_log

Edwards Lifesciences Expects 2025 Sales Of $5.6B-$6B Vs. Consensus Of $5.91B, With Adjusted EPS Of $2.40-$2.50 Versus Consensus Of $2.44, Reaffirms 2024 Constant Currency Sales Growth Guidance Of 8%-10%

Benzinga ·  Dec 4 05:07

2025 Guidance

Sales

$5.6 - $6.0 billion

(8% - 10% constant currency growth)

TAVR

$4.1 - $4.4 billion

(5% - 7% constant currency growth)

TMTT

$500 - $530 million

(50% - 60% constant currency growth)

Surgical

$970 million - $1.05 billion

(mid-single digit constant currency growth)

FX Impact on Sales

~$100 million unfavorable

(~2pt downside to reported growth)

Adjusted Gross Profit Margin78% - 79%
Adjusted Operating Margin27% - 28%
Tax Rate15% - 18%
Adjusted EPS$2.40 - $2.50
Diluted Shares Outstanding585 – 595 million
  • Increasing contribution from an expanding set of structural heart therapies in 2026 and beyond; targeting 10% average annual total company sales growth and double-digit EPS growth
    • Mid-to-high single digit TAVR growth driven by EARLY TAVR and PROGRESS
    • TMTT increasing contribution to growth, reaching $2 billion by 2030
    • Increasing contribution from new therapeutic areas including Structural Heart Failure and AR
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment